What is Elesclomol?

Elesclomol is a biologic that triggers apoptosis (programmed corpuscle death) in blight cells. It is getting developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has accustomed both fast clue and drop biologic cachet from the U.S. Food and Biologic Administration for the analysis of metastatic melanoma. Synta Pharmaceuticals appear on February 26, 2009 the abeyance of all analytic trials involving Elesclomol due to assurance concerns. In March 2010, Synta appear that the FDA had accustomed resuming analytic development of elesclomol, and that they known to admit one or added analytic trials for elesclomol in the additional bisected of the year.

In a small, randomized appearance II study, elesclomol was crystalline to decidedly access progression-free adaptation in humans with metastatic melanoma if accustomed in accession to paclitaxel (Taxol).

Elesclomol induces oxidative accent by afflictive a accretion of acknowledging oxygen breed aural blight cells. Elesclomol requires a redox active metal ion to function. The Cu(II) circuitous is 34 times added almighty than the Ni(II) circuitous and 1040-fold added almighty than the Pt(II) complex.